Most patients who discontinue Retatrutide do so during weeks 4-12 when GI symptoms peak
Form Health's approach is to offer patients frequent touch points with clinicians to help support obesity management, noted Florencia Halperin, M.D., Form Health's chief medical officer and a Harvard Medical School-trained endocrinologist
That coverage gap explains why cheaper compounded options gained popularity
Unlike other weight-loss injections, retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously, whereas typical injections target one or two of these receptors
The Science Behind Semaglutide-Related Hair Loss Semaglutide and hair loss share a complex connection that involves several biological mechanisms
FEMS Microbiol Lett 248: 241248